Use of TYRX's AIGISRx Antibacterial Envelope significantly reduced infection rates in patients undergoing pacemaker and implantable defibrillator implants, who were at high risk of surgical infections, according to a study presented today at the American College of Cardiology 61st Annual Scientific Session in Chicago.
The 20-month retrospective cohort study looked at infection rates experienced by 209 patients with recognized risk factors for infection whose cardiac implantable electronic device procedures included use of the implanted AIGISRx Envelope. These infection rates were compared with the infection rates experienced by a control cohort of 671 patients with matched risk factors.
The researchers found no CIED infections in patients who received AIGISRx implants after 90 days, compared to 15 infections in the control group.
Learn more about TYRX.
The 20-month retrospective cohort study looked at infection rates experienced by 209 patients with recognized risk factors for infection whose cardiac implantable electronic device procedures included use of the implanted AIGISRx Envelope. These infection rates were compared with the infection rates experienced by a control cohort of 671 patients with matched risk factors.
The researchers found no CIED infections in patients who received AIGISRx implants after 90 days, compared to 15 infections in the control group.
Learn more about TYRX.